The Conatus Pharmaceuticals Inc (CNAT) to Post FY2018 Earnings of $2.18 Per Share, SunTrust Banks Forecasts

The Conatus Pharmaceuticals Inc (CNAT) to Post FY2018 Earnings of $2.18 Per Share, SunTrust Banks Forecasts

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – Investment analysts at SunTrust Banks lowered their FY2018 earnings per share estimates for Conatus Pharmaceuticals in a research report issued to clients and investors on Thursday. SunTrust Banks analyst J. Boris now forecasts that the biotechnology company will post earnings of $2.18 per share for the year, down from their previous forecast of $2.46.

CNAT has been the subject of several other research reports. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. Aegis reissued a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Monday. FBR & Co reissued an “outperform” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Stifel Nicolaus reissued a “buy” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, March 17th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $13.25.

CNAT has been the subject of several other research reports. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. Aegis reissued a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Monday. FBR & Co reissued an “outperform” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Stifel Nicolaus reissued a “buy” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, March 17th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $13.25. Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 0.2594% during midday trading on Monday, hitting $5.5755. The stock had a trading volume of 361,400 shares. The company’s market capitalization is $145.87 million. The stock’s 50-day moving average is $6.79 and its 200-day moving average is $4.47. Conatus Pharmaceuticals has a 1-year low of $1.45 and a 1-year high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.20. The company had revenue of $7 million during the quarter, compared to the consensus estimate of $5.88 million. During the same period last year, the firm posted ($0.35) EPS. Hedge funds have recently bought and sold shares of the stock. Courage Capital Management LLC increased its stake in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 51,590 shares in the last quarter. Morgan Stanley increased its stake in Conatus Pharmaceuticals by 265.6% in the first quarter. Morgan Stanley now owns 67,095 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 48,741 shares in the last quarter. Geode Capital Management LLC increased its stake in Conatus Pharmaceuticals by 21.4% in the first quarter. Geode Capital Management LLC now owns 104,972 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 18,512 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Conatus Pharmaceuticals by 93.1% in the first quarter. Vanguard Group Inc. now owns 767,517 shares of the biotechnology company’s stock valued at $4,428,000 after buying an additional 369,973 shares in the last quarter. 15.90% of the stock is owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Conatus Pharmaceuticals Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment